Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct 1;15(1):150.
doi: 10.1186/s12985-018-1066-8.

Satisfactory virological response and fibrosis improvement of sofosbuvir-based regimens for Chinese patients with hepatitis C virus genotype 3 infection: results of a real-world cohort study

Ya-Chao Tao  1 , Rong Deng  1 , Meng-Lan Wang  1 , Duo-Duo Lv  1 , Man Yuan  1 , Yong-Hong Wang  1 , En-Qiang Chen  2 , Hong Tang  3
Affiliations

Satisfactory virological response and fibrosis improvement of sofosbuvir-based regimens for Chinese patients with hepatitis C virus genotype 3 infection: results of a real-world cohort study

Ya-Chao Tao et al. Virol J. .

Abstract

Background: Chronic hepatitis C virus (HCV) genotype (GT) 3 infection with advanced liver disease has emerged as a challenging to treat by direct-acting antivirals (DAAs), but the efficacy of DAAs in Chinese HCV-GT3 patients is rarely reported. This study aimed to analyze the efficacy of sofosbuvir (SOF)-based regimens in Chinese patients with HCV-GT3 and compensated liver disease.

Methods: This was a registered retrospective study. All patients had completed at least 12 weeks SOF-based regimens therapy (with or without RBV), and were followed up for at least 24 weeks after therapy discontinuation. The primary endpoint was sustained virological response 24 weeks after end of therapy (SVR24).

Results: A total of 102 patients who completed at least 12 weeks therapy were finally included, with 57 in SOF + Daclatasvir (SOF + DCV), 24 in SOF + DCV + ribavirin (RBV) and 21 in SOF/Velpatasvir (SOF/VEL). The total SVR24 rate was achieved in 90.20% (92/102), with 85.96% (49/57) in SOF + DCV, 91.67% (22/24) in SOF + DCV + RBV and 100.00% (21/21) in SOF/VEL. Among 10 relapsed patients (8 in SOF + DCV and 2 in SOF + DCV + RBV), the short course (12 weeks) of therapy and no RBV addition may be the leading cause. In this cohort, the SVR24 rate was not statistically different between patients with and without cirrhosis (81.82% [27/33] vs. 94.20% [65/69], P = 0.073). Additionally, both FIB-4 (4.03 vs. 2.08, P < 0.001) and APRI (2.15 vs. 0.68, P < 0.001) scores were significant improved from baseline to week 24 after completion of therapy, regardless of the presence of cirrhosis.

Conclusion: SOF-based regimens are highly effective in viral clearance and fibrosis remission for Chinese patients with HCV-GT3 infection. If available, SOF/VEL should be first considered.

Keywords: Chronic hepatitis C; Direct-acting antivirals; Genotype 3; Hepatitis C virus; Sofosbuvir-based regimens.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

This study was approved by the Ethics Committee of West China Hospital, Sichuan University.

Consent for publication

All authors approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
The virological responses at different time-points for CHC patients receiving SOF-based regimens
Fig. 2
Fig. 2
The virological responses at different time-points for CHC patients with and without cirrhosis
Fig. 3
Fig. 3
The virological responses in patients receiving 12-week or 24-week SOF + DCV ± RBV therapy
Fig. 4
Fig. 4
The improvement of FIB-4 (a) and APRI (b) among patients with receiving SOF-based regimens
Fig. 5
Fig. 5
The improvement of FIB-4 (a) and APRI (b) among patients with and without cirrhosis
Fig. 6
Fig. 6
The improvement of FIB-4 (a) and APRI (b) among patients with SVR24 and virus relapse
See this image and copyright information in PMC

References

    1. Bennett H, Waser N, Johnston K, Kao JH, Lim YS, Duan ZP, Lee YJ, Wei L, Chen CJ, Sievert W, et al. A review of the burden of hepatitis C virus infection in China, Japan, South Korea and Taiwan. Hepatol Int. 2015;9:378–390. doi: 10.1007/s12072-015-9629-x. - DOI - PubMed
    1. Polaris Observatory HCVC Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:161–176. doi: 10.1016/S2468-1253(16)30181-9. - DOI - PubMed
    1. Bochud PY, Cai T, Overbeck K, Bochud M, Dufour JF, Mullhaupt B, Borovicka J, Heim M, Moradpour D, Cerny A, et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol. 2009;51:655–666. doi: 10.1016/j.jhep.2009.05.016. - DOI - PubMed
    1. Probst A, Dang T, Bochud M, Egger M, Negro F, Bochud PY. Role of hepatitis C virus genotype 3 in liver fibrosis progression--a systematic review and meta-analysis. J Viral Hepat. 2011;18:745–759. doi: 10.1111/j.1365-2893.2011.01481.x. - DOI - PubMed
    1. Kanwal F, Kramer JR, Ilyas J, Duan Z, El-Serag HB. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. Hepatology. 2014;60:98–105. doi: 10.1002/hep.27095. - DOI - PMC - PubMed

Publication types

MeSH terms